{"id":"W2762638624","doi":"10.1200/jco.2017.35.15_suppl.9500","title":"A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Click Chemistry and Applications","field":"Chemistry","cited_by":63,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Ipilimumab; Internal medicine; Discontinuation; Adverse effect; Melanoma; Adjuvant; Toxicity; Neutropenia; Oncology; Phases of clinical research; Clinical endpoint; Gastroenterology; Randomized controlled trial; Surgery; Cancer; Immunotherapy; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003466025,0.0003346142,0.003220499,0.00006277052,0.0003089748,0.00003025024,0.001380351,0.000553307,0.0004658235],"category_scores_gemma":[0.01913024,0.0002054369,0.0008633528,0.00009228323,0.001092309,0.0001489821,0.0006014245,0.001236598,0.000001658221],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001340315,"about_ca_system_score_gemma":0.0005773973,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001808424,"about_ca_topic_score_gemma":0.0002251655,"domain_scores_codex":[0.9936988,0.0005258242,0.004602571,0.0004692998,0.0003872666,0.0003162003],"domain_scores_gemma":[0.9734204,0.01623321,0.008248813,0.001219384,0.0006058024,0.0002723834],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9166134,0.01411522,0.0003330506,0.0001130284,0.001688845,0.0000325547,0.0006364686,0.00001442797,0.008432331,0.00003712279,0.000815009,0.05716856],"study_design_scores_gemma":[0.9316733,0.03196286,0.007472451,0.0003530433,0.002948213,0.00005068116,0.001136109,0.000474632,0.02051966,0.0003687773,0.002762373,0.000277841],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9962245,0.0001632532,0.0001029688,0.001281052,0.0007874249,0.0008788501,0.0001609657,0.00001384371,0.0003871689],"genre_scores_gemma":[0.9974208,0.0005624698,0.0005381448,0.00002830816,0.0007137315,0.0000615287,0.00002085754,0.0000340148,0.0006201534],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05689072,"threshold_uncertainty_score":0.989132,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0839105979199141,"score_gpt":0.4396343322820914,"score_spread":0.3557237343621772,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}